Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Trial Profile

Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Opioid abuse
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Apr 2018 As the MR talks about the results and based on company pipeline I have assumed trial status as completed. Patients assumed as Volunteers.
    • 18 Apr 2018 According to Opiant Pharmaceuticals media release, the company has been awarded a grant of approximately $7.4 million from the National Institutes of Healths National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), the grant follows encouraging data from this study.
    • 20 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top